Form 4: 2seventy bio Director Sarah Glickman Reports Stock Option Grant and RSU Vesting

Director Sarah Glickman of 2seventy bio, Inc. reports the acquisition of stock options and vesting of restricted stock units (RSUs) on June 10, 2024.

Summary

• On June 10, 2024, Sarah Glickman, a director of 2seventy bio, Inc., reported transactions involving the company's stock.
• Glickman acquired 12,050 shares of common stock through the vesting of restricted stock units (RSUs) at a price of $0.00, and disposed of 12,050 shares.
• She also acquired options to purchase 24,100 shares of common stock at an exercise price of $3.93.
• Following these transactions, Glickman beneficially owns 27,652 shares of common stock and options to purchase 24,100 shares.
• The RSUs and options vest 100% on the earlier of June 10, 2025, or the date of the next annual meeting of stockholders.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it's a standard regulatory filing detailing stock transactions. The vesting of RSUs and granting of options are generally seen as a positive sign, but it's not overwhelmingly so.

Positives

• The acquisition of stock options and vesting of RSUs could indicate confidence in the company's future performance from a board member.

Future Outlook

The vesting schedule of the RSUs and stock options is contingent on the earlier of June 10, 2025, or the date of the next annual meeting of stockholders.

Industry Context

This is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates